STOCK TITAN

Rhythm Pharmaceuticals (RYTM) DEF 14A Filings

RYTM NASDAQ

Here are the DEF 14A proxy statements from Rhythm Pharmaceuticals, Inc. (RYTM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RYTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RYTM filings page.

Rhea-AI Summary

Rhythm Pharmaceuticals is holding a virtual 2026 Annual Meeting on June 24, 2026 at 2:00 p.m. Eastern to vote on key governance matters. Stockholders will elect two Class III directors, ratify Ernst & Young LLP as auditor for 2026, and approve an advisory Say-on-Pay vote on executive compensation.

Holders of 68,530,107 shares of common stock as of April 27, 2026, and certain Series A Convertible Preferred Stock holders subject to conversion limits, may vote online, by phone, mail, or during the webcast. The company highlights its classified board, independent committees, and expanding ESG and human capital initiatives, including low 2025 employee turnover and recognition as a top workplace.